Cogentis Therapeutics Inc.

Columbia, MD

UEI
T5K6EP6DD251
CAGE
7FCZ0
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Veteran Owned Business
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
10668 Quarterstaff Rd, Columbia, MD 21044, USA
Founded
2015
Employees
1-10
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Development of a synthetic, cell-permeable peptide for the inhibition of CDK5-P25 hyperactivity in amyotrophic… R44NS124471 National Institute of Neurological Disorders and Stroke (NIH) $5,483,460
Development of CDK5-P25 modulator to treat alzheimer's disease and frontotemporal dementia R43AG062058 National Institute on Aging (NIH) $732,659

SBA capabilities narrative

From the vendor's SBA profile

Developing new therapies for Alzheimer's and related dementias.

Quick answers

Is Cogentis Therapeutics Inc. registered in SAM.gov?

Yes. Cogentis Therapeutics Inc.'s SAM.gov registration is active through July 20, 2027.

What is Cogentis Therapeutics Inc.'s most recent federal award?

Cogentis Therapeutics Inc.'s most recent federal grant award is Development of a synthetic, cell-permeable peptide for the inhibition of CDK5-P25 hyperactivity in amyotrophic… (R44NS124471), from National Institute of Neurological Disorders and Stroke (NIH), on September 22, 2021.

On GovTribe

See Cogentis Therapeutics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login